Composition for treating senescence-related brain dysfunction of subject and application thereof

By reversing the transcriptome changes in cell type associated with aging using GLP-1R agonist, the complexity of brain dysfunction and treatment difficulties caused by aging were solved, and the cognitive function and brain structure of aged mice were significantly improved.

CN118987224AInactive Publication Date: 2024-11-22THE CHINESE UNIVERSITY OF HONG KONG
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411145454.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-12-16
Filing Date
2021-12-16
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The brain dysfunction caused by aging is complex and lacks effective targeted treatments. Existing anti-aging drug treatments face great challenges and are difficult to reverse or slow down the brain deterioration and neurodegenerative changes associated with aging.

Method used

Using GLP-1R agonists, such as exenatide, liraglutide, etc., these agonists are administered to subjects to reverse and inhibit transcriptome changes and functional changes in cell type related to aging, including neurons, gels, etc., by administering these agonists to the subjects. Plastic cells, parietal cells, etc., improve cognitive function and brain structural changes.

Benefits of technology

GLP-1R agonists can reverse aging-related transcriptome changes in various cell types, improve cognitive function, slow or reverse aging-related brain function decline, and significantly improve spatial memory and brain function in aged mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987224A_ABST
    Figure CN118987224A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicine, and provides a composition for treating brain function decline in the aging process and application of the composition, and the composition comprises a GLP-1R agonist and is used for treating aging-related brain dysfunction. In some embodiments, the GLP-1R agonist is exenatide, liraglutide, lisinide, albiglutide, dulatide, semeglutide, tasiglutide, PF-06882961, OWL-833, TTP-273, or any other molecule that activates GLP-1R. The invention also relates to a method for preparing the GLP-1R agonist.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application is a divisional application of the parent application with application number: CN2021800937328, application date: December 16, 2021. This application claims the benefit of the U.S. patent application with application number 63 / 126,122 filed on December 16, 2020, the entire contents of which are incorporated by reference into this application, including any tables, charts or drawings. Technical Field

[0003] The present invention relates to the field of medical technology, and in particular to a composition for treating aging-related brain dysfunction in a subject and an application thereof. Background Art

[0004] Aging has long been considered an irreversible process. Almost all cellular processes are associated with or affected by aging, from metabolism, stress response, immune response, cellular senescence, to gene expression and genome stability (Almanzar et al., "A single-cell transcriptomic atlas characterizes ageing tissues in the mouse", Nature, vol. 583, pp. 590-595 (2020)). These complex molecular changes may lead to changes in the cellular state and composition of many organs of the body, manifesting as aging-related functional decline. In the brain, hallmarks of aging include: (1) mitochondrial dysfunction; (2) dysregulated energy metabolism; (3) intracellular accumulation of oxidatively damaged proteins, nucleic acids, and lipids; (4) impaired cellular “waste disposal” mechanisms (i.e., autophagy, lysosomal, and proteasome function); (5) impaired adaptive stress response signaling; (6) impaired DNA repair; (7) abnormal neuronal network activity; (8) dysregulated neuronal calcium signaling and processing; (9) stem cell exhaustion; and (10) inflammation (MP Mattson and T V Arumugan, “Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States,” Cell Metabolism, vol. 27, pp. 1176–1199 (2018)). Given the complexity of the biological changes involved and the lack of an easily targetable set of driver pathways, anti-aging drug treatments are considered extremely challenging. Molecular and cellular changes in the aging brain contribute to its functional decline and predispose it to stroke and neurodegeneration (e.g., Alzheimer's and Parkinson's diseases). As human life span increases, the population suffering from aging-related brain diseases has increased dramatically. Slowing down or even reversing these changes in the aging brain could provide a strategy for primary prevention or even treatment of these diseases.

[0005] Glucagon-like peptide-1 (GLP-1) is a peptide hormone that is secreted peripherally by intestinal L cells to enhance glucose-dependent insulin release and is centrally produced in the brain by preproglucagon neurons in the nucleus of the solitary tract (Holt et al., "Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food", Diabetes, Vol. 68, pp. 21-33 (2018)). In the past decade, a variety of pharmacokinetically optimized GLP-1 receptor (GLP-1R) agonists (GLP-1RAs) have been approved for the clinical treatment of diabetes. In addition to treating diabetes, evidence from cellular and animal models of neurodegeneration and increased neurogenesis supports a role for GLP-1R stimulation in neurotrophy and neuroprotection (Salcedo et al., “Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders,” British Journal of Pharmacology, Vol. 166, pp. 1586-1599 (2012); Grieco et al., “Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases,” Frontiers in Neuroscience, Vol. 13 (2019);During et al., "Glucagon-like peptide-1 receptor is involved in learning and neuroprotection", Nature Medicine, Vol. 9, pp. 1173-1179 (2003); US6969702B2 - Compounds and methods for increasing neurogenesis; Isacson et al., "The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test", European Journal of Pharmacology, Vol. 650, pp. 249-255 (2011) (1, 2, 3-5);During et al., "Glucagon-like peptide-1 receptor is involved in learning and neuroprotection," Nature Medicine, Vol. 9, pp. 1173-1179 (2003) showed that GLP-1R is involved in learning and neuroprotection. Intracerebroventricular (icv) administration of GLP-1 and [Ser(2)]exendin(l-9) to 8-week-old rats enhanced associative and spatial learning through the GLP-1R. Peripherally administered [Ser(2)]exendin(l-9) was also active. Isacson et al. (Isacson et al., "The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test," European Journal of Pharmacology, Vol. 650, pp. 249-255 (2011)) have demonstrated that intraperitoneal (IP) injection of exendin-4 improves hippocampal-related reference memory performance and decreases immobility in the forced swim test. Notably, recent clinical studies have provided compelling evidence that GLP-1RAs exhibit neuroprotective effects beyond those produced by glycemic control, thereby reducing the incidence of cognitive decline and Parkinson's disease (PD) in patients with diabetes (Cukierman-Yaffe et al., "Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial," Lancet Neurology, vol. 19, pp. 582-590 (2020);Brauer et al., “Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes,” Brain (2020), https: / / doi.org / 10.1093 / brain / awaa262. In addition, in nondiabetic patients, GLP-1RAs can slow the progression of established Alzheimer's disease (AD) and PD (Gejl et al., "In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial", Frontiers in Aging Neuroscience, vol. 8, p. 108 (2016); Athauda et al., "Exenatide once weekly versus placebo in Parkinson's disease: a randomized, double-blind, placebo-controlled trial"). 390, pp. 1664-1675 (2017)). Mechanistically, in addition to reducing neuroinflammation in animal models of neurodegeneration (Cai et al., "Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP / PS1 / tau mouse model of Alzheimer's disease", Biochem Bioph Res Co, vol. 495, pp. 1034-1040 (2018);Yun et al., “Block of Al astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease,” Nature Medicine, vol. 24, pp. 931-938 (2018); Zhao et al. demonstrated that treatment with exenatide, a GLP-1RA, partially reversed senescence-associated transcriptomic changes in brain endothelial cells (ECs) and reduced nonspecific blood-brain barrier (BBB) ​​leakage (Zhao et al., “Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain,” Nat Commun, vol. 11, pp. 4413 (2020)).

[0006] Aging is the process of getting older. The term refers especially to mammals. In a broader sense, aging can refer to a single cell or to an organ within an organism. In humans, aging represents the cumulative changes in an individual over time. Aging is a major risk factor for common diseases in developed countries: cancer, cardiovascular disease, and neurodegenerative diseases (Niccoli and Partridge, "Ageing as a risk factor for disease," Current Biology, vol. 22: R741-R752 (2012)). The cause of aging is still unclear. One existing theory is the damage theory, according to which accumulated damage leads to a progressive loss of physiological integrity, resulting in impaired function and increased likelihood of death (López-Otín et al., "The hallmarks of aging," Cell, vol. 153, p. 1194 (2013)).

[0007] Aging involves nearly all cell types and cellular processes. Moreover, the characteristics of brain aging are different from those of neurodegenerative diseases with specific manifestations (e.g., AD, PD, and Huntington's disease). Given the complexity of the biological changes involved and the lack of an easily targetable set of driver pathways, anti-aging drug treatments are considered extremely challenging (if feasible). Therefore, there is a need to slow down or even reverse the transcriptomic and functional changes in the aging brain. Summary of the invention

[0008] Methods of treating a subject with an aging-related brain disease are described herein. Aspects of the methods include administering a GLP-1R agonist to a subject in need thereof, e.g., an individual at risk of developing or suffering from an aging-related brain disease. For example, aging-related brain diseases include aging-related cognitive impairment and structural, functional, or molecular changes in the brain.

[0009] In certain embodiments, the methods involve treating a subject who may be at risk for developing or suffering from a brain disease resulting from natural aging.

[0010] In certain embodiments, the subject who may be at risk of developing or suffering from an aging-related brain disease has transcriptome changes and functional changes in multiple cell types in the brain, including: neurons, e.g., mature neurons (mNeur) and immature neurons (imNeur); glial cells, e.g., astrocytes (AC), oligodendrocyte precursor cells (OPC), microglia (MG) and oligodendrocytes (OLG); mural cells, e.g., pericytes (PC) and smooth muscle cells (SMC); choroid plexus cells (CPC); hemoglobin-expressing vascular cells (Hb_EC); and monocytes (MNC).

[0011] In certain embodiments, the subject may be at risk for developing or suffering from an aging-related brain disease that can be treated using a GLP-1R agonist (GLP-1RA), such as exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, tasiglutide, PF-06882961, OWL-833 and / or TTP-273.

[0012] In certain embodiments, the GLP-1RA treatment can reverse and / or inhibit the transcriptomic changes and functional changes that occur in multiple cell types in the brain, including: neurons, e.g., mature neurons (mNeur) and immature neurons (imNeur); glial cells, e.g., astrocytes (AC), oligodendrocyte precursor cells (OPC), microglia (MG) and oligodendrocytes (OLG); mural cells, e.g., pericytes (PC) and smooth muscle cells (SMC); choroid plexus cells (CPC); hemoglobin-expressing vascular cells (Hb_EC); and monocytes (MNC). BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1A UMAP visualization of the major cell type clusters identified and analyzed in the mouse brain is shown. AC: astrocyte; OPC: oligodendrocyte precursor cell; MG: microglia; MAC: perivascular macrophage; OLG: oligodendrocyte; SMC: smooth muscle cell; PC: pericyte; EC: endothelial cell. Numbers in brackets: cell number of the corresponding cell type;

[0014] Figure 1B UMAP visualization of single-cell transcriptomes from young adult mouse brain is shown. Numbers in brackets: number of cells in that group (n = 3 animals in that group);

[0015] Figure 1C UMAP visualization of single-cell transcriptomes from aged adult mouse brain is shown. Numbers in brackets: number of cells in that group (n = 3 animals in that group);

[0016] Figure 1D Shown is a UMAP visualization of the single-cell transcriptome of the brain of aged mice treated with GLP-1RA (Exenatide). Numbers in brackets: number of cells in the group (n = 3 animals in the group);

[0017] Figure 2A Shown are senescence-associated expression changes (x-axis) plotted against expression changes after GLP-1RA treatment (y-axis) in glial (AC: astrocytes; OPC: oligodendrocyte precursor cells; MG: microglia; and OLG: oligodendrocytes), vascular (EC: endothelial cells; PC: pericytes; SMC: smooth muscle cells) cell types, and perivascular macrophages (MACs). Each dot represents a differentially expressed gene (DEG). Gray line: best fit line obtained by linear regression;

[0018] Figure 2B The ratio of DEGs reversed in different cell types and the Figure 2AThe slope of the best fit line obtained from the linear regression shown in ;

[0019] Figure 3 Aging-related expression changes (x-axis) are plotted against expression changes after GLP-1RA treatment (y-axis) in neurons (mNeur: mature neurons; imNeur: immature neurons; MG: microglia; and OLG: oligodendrocytes), monocytes (MNCs), choroid plexus cells (CPCs), and hemoglobin-expressing vascular cells. Each point represents a differentially expressed gene (DEG). Gray line: best fit line obtained by linear regression;

[0020] Figure 4 Shown are functional pathways with significant enrichment in the most significant aging-associated expression changes reversed by GLP-1RA treatment in different brain cell types;

[0021] Figure 5 Shown are changes in expression of selected functionally important genes in AC, MG, and SMC during aging and after GLP-1RA treatment;

[0022] Figure 6 Improvement of spatial memory in aged mice treated with GLP-1RA in the Y-maze test is shown.15 to 17 month old C57BL / 6 mice were treated daily with saline vehicle or 5 nmol exenatide per kg body weight (bw) for 2-4 months. DETAILED DESCRIPTION

[0023] definition

[0024] The scope provided herein should be understood as a shorthand expression of all values ​​in the range. For example, the scope of 1 to 20 should be understood as including any number, combination of numbers or subranges in the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20, and all intermediate decimal values ​​between the above integers, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 and 1.9. About subranges, specifically consider "nested subranges" extending from any end point of a certain scope. For example, the nested subranges of exemplary ranges 1 to 50 can include 1 to 10, 1 to 20, 1 to 30 and 1 to 40 in one direction, or include 50 to 40, 50 to 30, 50 to 20 and 50 to 10 in another direction.

[0025] As used herein, "decrease" refers to a negative change and "increase" refers to a positive change, wherein the negative or positive change is at least 0.001%, 0.01%, 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

[0026] The transitional term "comprising," which is synonymous with "including" or "containing," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. In contrast, the transitional term "consisting of" excludes any elements, steps, or ingredients not specified in the claim. The transitional term "consisting essentially of" limits the scope of the claim to the specified materials and steps "and materials and steps that do not materially affect the basic and novel characteristics of the invention." Use of the term "comprising" contemplates other embodiments of "consisting of" or "consisting essentially of the recited ingredients."

[0027] Unless otherwise specified or obvious from the context, the term "or" as used herein should be understood to be inclusive. Unless otherwise specified or obvious from the context, the terms "a", "and" and "the" as used herein should be understood to be singular or plural.

[0028] Unless otherwise specified or apparent from the context, the term "approximately" as used herein is to be understood as being within the normal tolerance range in the art, e.g., within 2 standard deviations of the mean. "Approximately" may be understood as being within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the specified value. Unless otherwise indicated in the context, all numerical values ​​provided herein are modified by the term "approximately".

[0029] As used herein, "pharmaceutically acceptable" means compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.

[0030] As used herein, "therapeutically effective amount," "therapeutically effective dose," "effective amount," and "effective dose" are used to refer to an amount or dose of a compound or composition that, when administered to a subject, is capable of treating or ameliorating a condition, disease, or disorder in a subject, or an amount or dose that is capable of enhancing the health or function of an organ, tissue, or body system. In other words, the amount is "therapeutically effective" when administered to a subject. The actual amount will vary depending on a variety of factors, including, but not limited to: the specific condition, disease, or disorder being treated or ameliorated; the severity of the condition; the specific organ, tissue, or body system in which the health or function is to be enhanced; the patient's weight, height, age, and health condition; and the route of administration.

[0031] As used herein, "treat," "alleviate," and "improve" (and grammatical variations of these terms) are used interchangeably. These terms refer to methods of obtaining beneficial or desired results, including but not limited to a therapeutic effect. A therapeutic effect is achieved by eradicating or ameliorating one or more physiological symptoms associated with the underlying disease so that an improvement is observed in the subject, although the subject may still be suffering from the underlying disease. Treatment includes delaying the onset of a disease or condition, delaying the onset of symptoms of a disease or condition, slowing, stopping or reversing the progression of a disease or condition, or any combination thereof. These terms refer to eradicating, reducing, improving or reversing the signs or symptoms of a health condition, disease or disorder to any extent, including but not requiring a complete cure of the condition, disease or disorder. Treatment may be a cure, improvement or partial improvement of a disorder. "Treatment" may also include improving or enhancing a condition or feature, for example, bringing the function of a particular system in the body to a higher state of health or homeostasis.

[0032] As used herein, the term "elderly" refers to a subject who is past middle age in an age group. Elderly refers to a subject of a particular age group, for example, 50 years or older, 60 years or older, 65 years or older, 70 years or older, or 75 years or older. Elderly subjects are preferably mammals, more preferably humans, even more preferably adults and are at least 50, 55, 60, 65 or 70 years old. More preferably, the patient is an elderly (adult) human patient who is old or older. Elderly patients can be male or female.

[0033] As used herein, the phrase "executive function" refers to a group of cognitive abilities that control and regulate other abilities and behaviors. Executive functions are higher-level abilities that influence more basic abilities such as attention, memory, and motor skills. Executive functions are necessary for goal-directed behavior and include the ability to start and stop actions, monitor and change behavior as needed, and plan future behavior when faced with new tasks and situations. Executive functions enable subjects to predict outcomes and adapt to changing situations. The ability to form concepts and the ability to think abstractly are often considered components of executive functions.

[0034] Age-related brain disorders

[0035] The brain's functions gradually decline along with other organs during aging. The brains of older people are at risk for developing or suffering from age-related disorders, which manifest as decreased learning and memory, attention, decision-making speed, sensory perception, and motor coordination.

[0036] In certain embodiments, subjects who would benefit from the treatments disclosed herein include individuals who are about at least 50, 60, 70, 80, 90 years old, and generally no older than 100 years old; between about 50 and 100 years old; or about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, or about 100 years old and are at risk of developing or having an aging-related disorder, e.g., cognitive impairment and / or measurable brain structural changes, functional changes, or molecular changes.

[0037] In certain embodiments, cognitive impairment can include various brain disorders, such as attention and concentration; learning tasks and concepts; memory; information processing; visual spatial function; speech production; language comprehension; verbal fluency; problem solving; decision-making and executive function. Cognitive impairment can be assessed by a variety of tests, such as memory, recall, visual spatial awareness, verbal fluency, expressive language, executive function, gait and dual tasks. Tests for detecting this difference include the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment Scale (MoCA) and its variants, the Alzheimer's Disease Assessment Scale Cognitive Part (ADAS-Cog) and the Clinical Dementia Rating (CDR) scale. Scores that meet any of the following criteria are considered to have cognitive impairment: MMSE scores of 26 or less, MoCA scores of 25 or less, ADAS-Cog scores of 12 or more, and CDR scores of 0.5 or more.

[0038] In certain embodiments, the changes in brain structure can be changes in brain volume (i.e., a decrease of 5%, 10%, 15%, 20% or more), gray matter structure, white matter structure, ventricular system structure, neurovascular system structure and integrity. Brain structural changes can be measured by imaging methods, such as magnetic resonance imaging (MRI), computed tomography (CT) or ultrasonography (US). Aging-related declines in these measurements are defined as changes in values ​​and / or patterns of changes in volume structure obtained by corresponding imaging or recording methods, which are located at the extremes of the distribution of the entire population or the same age group (e.g., the top or bottom 5%, 10%, 20%, 25%, 30%), or show changes when repeated measurements are made on the same subject over time (e.g., 5%, 10%, 15%, 20%, 25% or more).

[0039] In some embodiments, changes in brain function may refer to measurable changes in the brain that reflect changes in neuronal activity, metabolism, or neurovascular function. Changes in brain function may be measured by imaging methods, such as functional magnetic resonance imaging (fMRI), magnetic resonance imaging (MRSI), hyperpolarized carbon 13 ( 13C) Magnetic resonance spectroscopy imaging (MRSI), ultrasonography (US), positron emission tomography (PET), or single photon emission computed tomography (SPECT). Changes in brain function can also be recorded by electrophysiological methods, such as electroencephalography (EEG); intracortical electrode recordings; and deep brain electrode recordings, or magnetic field-based recording methods, including magnetoencephalography (MEG). Age-related decline in these measurements is defined as changes in values ​​and / or patterns of neuronal activity, metabolism, or neurovascular function obtained by the corresponding imaging or recording method, which are at the extremes of the distribution of the entire population or age group (e.g., top or bottom 5%, 10%, 20%, 25%, 30%), or show changes when repeated measurements are made on the same subject over time (e.g., 5%, 10%, 15%, 20%, 25% or more).

[0040] In certain embodiments, changes in brain molecules may refer to changes in measurable molecular levels in brain tissue or blood, such as changes in gene expression; DNA transcription; RNA translation; localization of DNA, RNA or protein in brain cells or tissues; and / or secretion or release of proteins, DNA, RNA, mitochondria, cellular components and / or mitochondrial components into the blood. The body fluid may be cerebrospinal fluid (CSF), blood or plasma. Aging-related changes in these measurements are defined as changes in values ​​and / or patterns of changes in brain molecules obtained by the corresponding methods, which are at the extremes of the distribution of the entire population or the same age group (e.g., top or bottom 5%, 10%, 20%, 25%, 30%), or show changes when repeated measurements are made on the same subject over time (e.g., 5%, 10%, 15%, 20%, 25% or more).

[0041] GLP-1R agonists

[0042] In certain embodiments, a GLP-1R agonist may be used in the methods of the present invention. A GLP-1R agonist is an agonist of the GLP-1 receptor. GLP-1 is a natural agonist of GLP-1R with a short duration of action. Several pharmacologically optimized GLP-1R agonists have been approved or are under development for clinical treatment of diabetes or neurodegenerative diseases (e.g., Alzheimer's disease and Parkinson's disease).

[0043] The activity of GLP-1R agonists can be determined by measuring the well-studied downstream signaling and regulatory pathways associated with GLP-1R activation, such as increased cAMP production, induction of ERK1 / 2 phosphorylation, enhanced intracellular calcium mobilization, and recruitment of β-arrestin 1 and β-arrestin 2.

[0044] Some non-limiting examples of GLP-1R agonists include exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, taseroglutide, PF-06882961, OWL-833, and TTP-273.

[0045] Dosage and Administration

[0046] In certain embodiments, the methods described herein provide a method for treating aging-related brain disorders. In one embodiment, the subject may be a mammal. In another embodiment, the subject may be a human, although the present invention is effective for all mammals. The method may include administering to the subject an effective amount of a pharmaceutical composition comprising a GLP-1R agonist that can reverse transcriptome changes and functional changes in the aging brain. The composition of the present invention may also include one or more pharmaceutically acceptable carriers and / or excipients, and may be formulated into preparations in the form of solid, semisolid, liquid or gas, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols. Pharmaceutically acceptable carriers are well known in the art and include aqueous solutions, such as water or buffered saline, or other solvents or vehicles such as polyethylene glycol, Tween-20 or olive oil or injectable organic esters. The dosage range of the agonist may depend on the efficacy. In certain embodiments, a large amount of agonists can produce the desired effect, for example, reversing transcriptome changes and functional changes in any major cell type in the aging brain, or reversing structural changes and / or functional changes in the aging brain. The dosage should not be too large, otherwise it will cause adverse side effects. In general, the dosage will vary depending on the agent used. In addition, the age, condition and gender of the subject can be determined by a person skilled in the art and used to determine the dosage. If any complications arise, the dosage can also be adjusted by the doctor.

[0047] In one embodiment, the composition is formulated as oral consumables, for example, food, capsule, pill or drinkable liquid. The health-promoting compound that can be delivered orally is any physiologically active substance that is delivered or delivered to the oral mucosa by preliminary absorption in the gastrointestinal tract. The composition can also be formulated as a solution that can be used by injection (including intravenous, abdominal, intramuscular, intrathecal or subcutaneous injection). In other embodiments, the composition of the present invention is formulated as by a patch via the skin or directly applied to the skin, to produce a local or systemic effect. The composition can also be used by sublingual, oral, rectal or vaginal administration. In addition, the composition can be sprayed into the nasal cavity to absorb, atomize, inhale by the oral cavity or nose, or use in the eye or ear by nasal mucosa.

[0048] Oral consumables according to the present invention are any preparation or composition suitable for consumption, nutritional supplementation, oral hygiene or pleasure, and are intended to enter the human or animal oral cavity to stay there for a period of time and then swallowed (e.g., edible food or pills) or taken out of the oral cavity again (e.g., chewing gum or oral hygiene products or medical mouthwashes). Although orally deliverable drugs can be formulated as oral consumables, and oral consumables can include orally administrable drugs, the two terms are not used interchangeably herein.

[0049] Orally consumables include all substances or products intended to be ingested by humans or animals in a processed, semi-processed or unprocessed state. This also includes substances that are added to orally consumables (especially foods and drugs) during production, treatment or processing and are intended to enter the human or animal oral cavity.

[0050] Oral consumables may also include substances intended to be swallowed by humans or animals and then digested in an unmodified, prepared or processed state. Oral consumables according to the present invention may also include a shell, coating or other covering intended to be swallowed or expected to be swallowed with the product.

[0051] In one embodiment, the oral consumable comprises a capsule, a pill, a syrup, an emulsion or a liquid suspension of the desired orally deliverable substance. In one embodiment, the oral consumable may comprise an orally deliverable substance in powder form, which may be mixed with water or another liquid to produce a drinkable oral consumable.

[0052] Carriers and / or excipients according to the present invention may include any and all solvents, diluents, buffers (e.g., neutral buffered saline, phosphate buffered saline, or alternatively Tris-HCl, acetate or phosphate buffers), oil-in-water or water-in-oil emulsions, aqueous compositions containing or containing organic co-solvents suitable for intravenous (IV) use, etc., solubilizers (e.g., polysorbate-65, polysorbate-80), colloids, dispersion media, vehicles, fillers, chelating agents (e.g., EDTA or glutathione), amino acids (e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, fragrances, thickeners (e.g., carbomer, gelatin or sodium alginate), coatings, preservatives (e.g., thimerosal, benzyl alcohol, polyquaternium salts), antioxidants (e.g., ascorbic acid, sodium metabisulfite), tonicity modifiers, absorption delaying agents, adjuvants, bulking agents (e.g., lactose, mannitol), etc. The use of carriers and / or excipients is well known in the pharmaceutical and supplement arts. Except insofar as any conventional media or agent is incompatible with the subject health promoting substance or adjuvant composition, a carrier or excipient is contemplated for use in the compositions of the present invention.

[0053] In one embodiment, said composition can be made into aerosol preparations, for example, so that it can be atomized or sucked.For example, the pharmaceutical preparations suitable for use in aerosol or spray form are solutions, suspensions or emulsions.Preparations for oral or nasal aerosols or inhalation administration can also be prepared (for example, including physiological saline, polyethylene glycol or ethylene glycols, DPPC, methylcellulose) with exemplary carriers, or mixed with powdered dispersants or fluorocarbons.Aerosol preparations can be put into pressurized propellants, for example, dichlorodifluoromethane, propane, nitrogen, fluorocarbons and / or other solubilizing agents or dispersants known in the art.As an illustration, delivery can be carried out by using any other delivery device in disposable delivery device, atomizing sprayer, breath-activated powder inhaler, aerosol metered dose inhaler (MDI) or numerous atomizer delivery devices available in this area.In addition, spray tents can also be used or directly applied by endotracheal intubation.

[0054] In one embodiment, the composition can be formulated for administration by injection, for example as a solution or suspension. The solution or suspension may include a suitable non-toxic, parenterally acceptable diluent or solvent (e.g., mannitol, 1,3-butylene glycol, water, Ringer's solution, or isotonic sodium chloride solution), or a suitable dispersant or wetting agent and suspending agent (e.g., sterile, non-irritating fixed oils, including synthetic monoglycerides or diglycerides) and fatty acids (including oleic acid). An illustrative example of a carrier for intravenous use includes a mixture of 10% USP grade ethanol, 40% USP grade propylene glycol or polyethylene glycol 600 and the remainder USP grade water for injection (WFI). Other exemplary carriers for intravenous use include: 10% USP grade ethanol and USP grade WFI; 0.01-0.1% triethanolamine (dissolved in USP grade WFI); or 0.01-0.2% dipalmitoyl diphosphatidylcholine (dissolved in USP grade WFI); and 1-10% squalene or parenteral vegetable oil-in-water emulsifiers. Water or physiological saline solutions and aqueous glucose and glycerol solutions can be preferably used as carriers, especially for injectable solutions. Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose (dissolved in WFI) and 0.01-0.1% triethanolamine (dissolved in 5% dextrose) or 0.9% sodium chloride (dissolved in USP grade WFI), or a 1:2 mixture or a 1:4 mixture of 10% USP grade ethanol, 40% propylene glycol, the balance being an acceptable isotonic solution, e.g., 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine (dissolved in USP grade WFI) and 1-10% squalene or a parenteral vegetable oil-in-water emulsifier.

[0055] In one embodiment, adjuvant composition can be formulated for applying on the skin by topical application, for example, as a local solution, it includes flushing fluid, spray, drops, lotion, gel, ointment, cream, foam, powder, solid, sponge, adhesive tape, steam, paste, tincture or transdermal patch.Except any pharmaceutically active carrier, the suitable preparation of topical application can also include emollient, for example, carnauba wax, hexadecanol, hexadecanol ester wax, emulsifying wax, aqueous lanolin, lanolin, lanolin alcohol, microcrystalline wax, paraffin, vaseline, polyethylene glycol, stearic acid, stearyl alcohol, white beeswax or yellow beeswax.In addition, these compositions can contain wetting agent (for example, glycerol, propylene glycol, polyethylene glycol, sorbitol solution and 1,2,6-hexanetriol) or penetration enhancer (for example, ethanol, isopropyl alcohol or oleic acid).

[0056] Other ingredients, such as buffers, carriers, viscosity modifiers, preservatives, flavoring agents, dyes, and other ingredients specific to the intended use, may be added to the compositions determined by those skilled in the art. Those skilled in the art will recognize that the above description is illustrative rather than exhaustive. In fact, many additional formulation techniques and pharmaceutically acceptable excipients and carrier solutions suitable for specific modes of administration are well known to those skilled in the art.

[0057] In certain embodiments, the dosage range will be about 0.001 mg / kg to about 1 g / kg. In some embodiments, the dosage range will be about 0.001 mg / kg to about 0.2 g / kg, about 0.001 mg / kg to about 0.1 g / kg, about 0.001 mg / kg to about 20 mg / kg, about 0.001 mg / kg to about 10 mg / kg, about 0.001 mg / kg to about 5 mg / kg, about 0.001 mg / kg to about 2 mg / kg, about 0.001 mg / kg to about 1 mg / kg, about 0.001 mg / kg to about 0.2 mg / kg, about 0.001 mg / kg to about 0.02 mg / kg, about 0.001 mg / kg to about 0.01 mg / kg. Alternatively, in some embodiments, the dosage range is about 0.01 g per kg body weight to about 1 g per kg body weight, about 0.05 g per kg body weight to about 1 g per kg body weight, about 0.1 g per kg body weight to about 1 g per kg body weight, about 0.2 g per kg body weight to about 1 g per kg body weight, about 0.25 g per kg body weight to about 1 g per kg body weight, about 0.5 g per kg body weight to about 1 g per kg body weight. In one embodiment, the dosage range is about 5 μg per kg body weight to about 50 μg per kg body weight.

[0058] GLP-1RAs that reverse aging-related brain disorders can be administered multiple times a day, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 times a day; once a day; less than once a day; once a week; once every two weeks; once a month; once every two months; once a quarter; twice a year; once a year; or continuously administered to achieve a therapeutically effective dose. The administration of the doses used herein can be repeated over a limited period of time, for example, the doses used herein can be administered daily for weeks, months or years. The duration of treatment depends on the subject's clinical progress and response to treatment. A therapeutically effective amount refers to an amount of GLP-1RA sufficient to produce measurable brain changes (see "Efficacy Determination" below). This effective amount can be administered in clinical trials as well as animal studies.

[0059] The GLP-1RAs useful in the present invention may be administered orally, intravenously, nasally, by inhalation, intraperitoneally, intramuscularly, subcutaneously, or intracavitary. In one embodiment, the GLP-1RAs used herein are administered to a patient orally or subcutaneously.

[0060] Efficacy determination

[0061] In one embodiment, the efficacy of a given treatment can be determined by the improvement of cognitive ability, which is measured by a variety of tests such as memory, recall, visual spatial awareness, verbal fluency, expressive language, executive function, gait, dual-task and multi-task. These can be reflected in the improvement of values ​​obtained by cognitive tests, including the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment Scale (MoCA) and its variants, the Alzheimer's Disease Assessment Scale Cognitive Part (ADAS-Cog) and the Clinical Dementia Rating (CDR) scale. Clinical improvement is defined as any of the following numerical changes: an increase in MMSE score, an increase in MoCA score, a decrease in ADAS-Cog score or a decrease in CDR score. The improvement of cognitive ability can also be reflected in the fact that any of these scores compared to age-matched populations has not decreased or has decreased at a slower rate, for example, the values ​​of MMSE, MoCA, ADAS-Cog or CDR have not changed, because these values ​​are expected to continue to decline with age.

[0062] In another embodiment, the efficacy of a given treatment can be determined by the reversal of aging-related structural changes in the brain, where these changes can be measured by imaging methods, such as magnetic resonance imaging (MRI); computed tomography (CT); and ultrasonography (US). In certain embodiments, the structural changes can be hippocampal atrophy, cortical atrophy, subcortical structural atrophy, cerebellar atrophy, global brain atrophy; frontal, temporal, parietal or occipital gray matter microbleeds; frontal, temporal, parietal or occipital white matter microbleeds; lacunes, infarcts, perivascular spaces, frontal, temporal, parietal or occipital white matter intensity changes and / or protein species aggregation. Improvement in structural changes can be in the form of: no new aging-related structural changes; values ​​remain constant over time; or the size of a metric quantifying the severity of structural changes changes. Protein species can be beta-amyloid, Tau, alpha-synuclein, TAR DNA binding protein 43 and / or prion protein present in cortical areas, subcortical areas or brainstem.

[0063] In another embodiment, the efficacy of a given treatment can be determined by reversal of aging-related changes in brain function, where these changes can be measured by imaging methods, such as functional magnetic resonance imaging (fMRI); magnetic resonance imaging (MRSI); hyperpolarized carbon 13 ( 13 C) Magnetic resonance spectroscopy imaging (MRSI); Ultrasound (US); Positron emission tomography (PET); and Single photon emission computed tomography (SPECT). Changes in brain function can also be recorded by electrophysiological methods, such as electroencephalography (EEG); intracortical electrode recording; deep brain electrode recording; or magnetic field-based recording methods, such as magnetoencephalography (MEG). These functional changes can be altered brain area activation patterns, neuronal activity, functional connectivity, blood-brain barrier leakage, resting blood flow, glucose consumption, metabolite concentrations, and neurovascular coupling and / or functional hyperemia. For each of these metrics, efficacy is defined as a reversal closer to the corresponding values ​​found in young subjects, or the absence of progression or naturally occurring aging-related changes in these values.

[0064] In another embodiment, the efficacy of a given treatment can be determined by reversal of aging-related molecular changes in the brain, where these changes can be assessed by measuring molecules in brain tissue or blood, such as gene expression; DNA transcription; RNA translation; localization of DNA, RNA or protein in brain cells or tissues; secretion or release of proteins, DNA, RNA, mitochondria, cellular components, mitochondrial components into the blood. The body fluid can be cerebrospinal fluid (CSF), blood and / or plasma.

[0065] In certain embodiments, differentially expressed genes (DEGs) and associated raw P values, P values ​​adjusted by false discovery rate (FDR), and / or the magnitude of change expressed by the natural logarithm of the multiple change (InFC) can be calculated for each cell type. In certain embodiments, the P value in the DEG is <0.05, preferably the P value adjusted by FDR is <0.05.

[0066] In certain embodiments, genes and subsequent transcribed mRNA and translated proteins that can be evaluated in the methods of the present invention include: immune response-related genes, such as C1qa, C1qb, C1qc, C4b, B2m, Tap2, H2-D1, H2-K1; synaptic modification-related genes, such as Sparcl1, Gpc6, Tgfb2, Megf10, Mertk, Chrdl1; homeostatic function-related genes, such as Kcnj10, Kcnn2, Slc1a2, Slc1a3, Slc6a1, Slc6a9, Slc6a11, Slc7a10, Slc7a11, Slc16a1, Srebf1, Gja1, Gjb6, Itpr2, Grm3, Gria2, Gabbr1, Gabbr2; homeostatic function-related genes in MG cells, such as Csf 2r and P2ry13; immune activation-related genes in MG cells, for example, Appe, Ccl3, Ccl4, Cd52, Cst7, Fabp5, Tyrobp, Cd14, Cd33, Ifngr1, Ly86, Map4k4; immune response suppression genes in MG cells, for example, Cd300a, Il10ra, and Il10rb; calcium signaling-related genes in SMCs, for example, Camk2g, Stim1, Gsn, Atp2a2, Inpp4b, Mcur1, S100a6, and Tspo; SMC contraction-related genes, for example, Mylk, Itga1, Mgh11, and Sorbs1; and cell adhesion and ECM remodeling in SMCs, for example, Col1a2, Lamb1, Itga7, Jam3, Lamb2, Itgb1, and Bsg.

[0067] Materials and methods

[0068] Animal subjects

[0069] All experimental procedures were approved in advance by the Animal Research Ethics Committee of the Chinese University of Hong Kong (CUHK) and performed in accordance with the Guide for the Care and Use of Laboratory Animals. C57BL / 6J mice were provided by the CUHK Laboratory Animal Service Center and maintained in a controlled temperature (22–23°C) environment with a 12-h light-dark cycle, with free access to standard mouse chow and water. Ambient humidity was maintained at <70% relative humidity. Male mice of two age groups (2–3 months and 18–20 months) were used for experiments unless otherwise stated. For the treatment groups, exenatide (5 nmol per kg body weight, Byetta, AstraZeneca LP, Cambridge, UK) or saline vehicle (0.9% w / v sodium chloride) was administered intraperitoneally (IP) (volume: 250 μl per 30 g body weight) once daily for 4–5 weeks before the experiment, unless otherwise stated.

[0070] Brain tissue dissociation and single cell isolation

[0071] An optimized dissociation protocol for isolating single brain cells from young and old mouse brain (Vanlandewijck, M. et al., "Primary isolation of vascular cells from murine brain for single cell sequencing," Protocol Exchange, https: / / doi.org / 10.1038 / protex.2017.159(2018) was adapted for use. Mice were deeply anesthetized and perfused intracardially with 20 ml of ice-cold phosphate-buffered saline (PBS). Mice were then rapidly sacrificed and the entire brain (except the cerebellum) was immersed in ice-cold Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher Scientific, Waltham, MA). Brain tissue was cut into small pieces and isolated into single cells using a modified version of the Neural Tissue Dissociation Kit (P) (130-092-628, Miltenyi Biotec, Bergisch Gladbach, Germany). Myelin debris was removed using the Myelin Removal Kit II (130-096-733, Miltenyi Biotec) according to the manufacturer's manual. Cell clumps were removed by continuous filtration through pre-wetted 70 μm (#352350, Falcon, Corning, NY) and 40 μm (#352340, Falcon) nylon cell strainers. Centrifuge at 300 xg for 5 min at 4° C. Resuspend the final cell pellet in 500-1000 μl FACS buffer (DMEM without phenol red (Thermo Fisher Scientific), supplemented with 2% fetal bovine serum (Thermo Fisher Scientific)).

[0072] Preparation, sequencing and alignment of single-cell libraries

[0073] Single cell RNA sequencing libraries were generated using Chromium single cell 3' kit v3 (10X Genomics, Pleasanton, California). Single cell suspensions with a density of 500-1000 cells per microliter in FACS buffer were added to the real-time polymerase chain reaction (RT-PCR) master mix, and then loaded into the single cell 3' chip together with single cell 3' gel beads and isolation oil according to the manufacturer's instructions. The RNA transcriptome from the single cell was uniquely barcoded and reversely transcribed in the droplet. According to the manufacturer's instructions, cDNA molecules were pre-amplified and pooled, and then library construction was performed. All libraries were quantified in the LightCycler 96 system (Roche Life Science, Penzberg, Germany) by Qubit and RT-PCR. The size profiles of the pre-amplified cDNA and sequencing libraries were detected by Agilent high sensitivity D5000 and high sensitivity D1000 screen tape systems (Agilent, Santa Clara, California), respectively. All single-cell libraries were sequenced using custom double-end sequencing with single-end tags (28 / 8 / 91-bp for v3 libraries) as recommended by 10X Genomics. All single-cell libraries were sequenced on the NextSeq500 system (Illumina) using the NextSeq 500 High Output v2 Kit (Illumina, San Diego, CA). An average of 5897.25 average reads were obtained per cell (range: 2,340-19,700), and an average of 2296.01 genes were detected per cell (range: 88-6,062). The library sequencing saturation averaged 68.73%. Data were aligned in Cell Ranger (v3.0.0, 10X Genomics).

[0074] Data quality control

[0075] Data processing and visualization were performed using custom scripts in R (v3.6.1) and the Seurat package (v3.1.5). The raw count matrix was generated by default parameters (using the mm10 reference genome). There were 106,832 cells in the primary count matrix. Genes expressed in less than five cells were removed, leaving a total of 21,259 genes. Among these genes, the SeuratFindVariableFeatures function identified 3,000 highly variable genes. The dataset was filtered to exclude low-quality cells based on the following criteria: (1) <5% or >95% UMI counts or gene counts, or (2) mitochondrial gene proportion >20%. For dimensionality reduction, principal component analysis (PCA) was applied to calculate the first 30 principal components. Clustering was performed by the Seurat functions FindNeighbors and FindClusters. The FindNeighbors function constructs a shared nearest neighbor (SNN) graph based on the first 50 principal components. Then, modularity optimization was performed on the SNN results for clustering (resolution parameter: 1.2). The clustering results are visualized using the unified manifold approximation and projection (UMAP).

[0076] Cell type identification

[0077] To identify primary cell types, known cell type-specific marker genes were used and their expression levels were examined in all 52 included initial clusters. In addition, clusters with double high expression of two or more cell type-specific marker genes were excluded. These clusters included clusters with high expression of endothelial and pericyte markers (corresponding to contamination of pericytes with endothelial debris). The remaining clusters were classified into 16 primary cell types (see Figures 1A to 1D ).

[0078] Calculation of differentially expressed genes

[0079] After quality control and cell type classification, gene count normalization and high-variance gene identification were applied to the raw data of the retained 78,490 cells for further analysis. Differentially expressed genes (DEGs) and associated raw P values, false discovery rate (FDR)-adjusted P values, and magnitude of change in expression as natural logarithm of fold change (InFC) were calculated for each cell type using the Seurat FindMarkers function and the MAST package (v1.8.2). Significant DEGs were defined as those with an FDR-adjusted P value < 0.05.

[0080] Pathway enrichment and disease association analysis

[0081] GeneAnalytics, an online general gene function analysis tool that contains more than one hundred data sources for pathway enrichment analysis, was used. Significant DEGs were converted to human gene homologs in a semi-automatic manner. Pathways with significant functional significance were manually identified from the literature review and classified and summarized, including metabolic pathways, immune response and cytokine signaling pathways, respiratory electron transport chain / ATP synthesis and glucose / energy metabolism pathways, gene expression / transcription and translation regulation pathways, calcium and other second messenger signaling pathways, cell type-specific pathways (e.g., SMC contraction), hormone signaling pathways, cell adhesion and extracellular matrix remodeling-related pathways.

[0082] Y-maze test

[0083] The Y-maze test was used to assess spatial memory. The Y-maze includes three closed arms, 30 cm long, 8 cm wide, and 15 cm high, made of white acrylic glass, forming an angle of 120 ° between each other. Visual cues were placed around the maze in the test room. The test included two trials. In the first trial, mice were allowed to explore the maze for 5 minutes when one of the arms was closed. During the 2 minutes between the two trials, the mice were returned to the home cage away from the test room. In the second trial, mice were allowed to freely explore all three arms of the maze for 5 minutes. The time spent in each arm was recorded from the video recording. Entering the arm is defined as the main body part of the mouse crossing the threshold of the central area and entering the arm. The percentage of time spent in the new arm (previously closed in the first trial) was calculated.

[0084] All patents, patent applications, provisional applications, and publications mentioned or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent not inconsistent with the explicit teachings of this specification.

[0085] Below are examples of processes for implementing the present invention. These examples should not be construed as limiting. Unless otherwise indicated, all percentages are by weight and all solvent mixture ratios are by volume.

[0086] Example

[0087] Example 1—Exenatide Treatment of Mice

[0088] Aging results in significant transcriptomic changes in multiple major brain cell types, including neurons; glial cells, such as astrocytes (AC), oligodendrocyte precursor cells (OPC), microglia (MG), and oligodendrocytes (OLG); and mural cells, such as endothelial cells (EC), pericytes (PC), and smooth muscle cells (SMC). Treatment with exenatide, a GLP-1R agonist, reverses these aging-associated transcriptomic signatures. Aging-associated expression changes reversed by GLP-1RA include both shared and cell-type-specific functional pathways associated with aging and neurodegeneration.

[0089] Single-cell transcriptome analysis was performed on young adult mice, aged mice, and aged mice treated with exenatide. Figures 1A to 1D As shown, the major cell type clusters identified and analyzed in the mouse brain were visualized by UMAP. The genome-wide expression changes of major cell types in the aging brain and their modulation by GLP-1RA treatment were analyzed. Significant DEGs (defined as P value < 0.05 after false discovery rate (FDR) adjustment) were calculated for each cell type to analyze their expression change patterns during aging and the effects of exenatide treatment. Figure 2A , Figure 2B and Figure 3 As shown, exenatide treatment universally reversed aging-associated transcriptome changes in most major cell types in the brain.

[0090] Expression changes reversed by GLP-1RA treatment were functionally relevant. Pathway enrichment analysis of the most significantly reversed DEGs for each cell type highlighted improvements in aging-associated expression changes involving a wide range of cellular functions, such as Figure 4As shown. In most cell types, these include genes that mediate glucose / energy, fat, and protein metabolic processes, as well as transcriptional and translational regulation. By pathway analysis, there are cell type-specific changes. In addition, the expression changes of some genes have significant functional effects. In ACs, aging-associated expression changes have been reported for genes that mediate immune responses, homeostatic function, and synaptic plasticity (MM Boisvert, GA Erikson, MN Shokhirev, NJ Allen, "The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain", Cell Reports, Vol. 22, pp. 269-285 (2018)). In this example, ACs from mice treated with GLP-1RA appear to partially revert to a younger phenotype, with multiple complement 1 component genes downregulated ( Figure 5 ), a subset of genes encoding synaptic modification-related proteins, metabolite receptors and transporters, neurotransmitter receptors, and ion channels were upregulated ( Figure 5 On the other hand, immune response and cytokine signaling-related genes were particularly prominent among the reversed DEGs in MG and MAC, followed by EC ( Figure 5 ). Previous studies have shown that microglia in the aging brain exhibit a proinflammatory phenotype (Hammond et al., "Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes", Immunity, Vol. 50, pp. 253-271.e6 (2019); A.F. Lloyd and V.E. Miron, "The pro-remyelination properties of microglia in the central nervous system", Nature Reviews Neurology, pp. 1-12 (2019)). After GLP-1RA treatment, MG showed upregulation of multiple homeostatic function-related genes and immune response suppression genes, and reversed the expression changes of multiple activation-related genes ( Figure 5In SMCs, post-treatment reversal of expression changes in important functional processes associated with age-related vascular stiffening, such as calcium signaling, extracellular matrix (ECM) remodeling, and contractile pathways, was found. Figure 4 and Figure 5 ).

[0091] Example 2—Exenatide treatment improves cognitive function in aged mice

[0092] To evaluate the effect of exenatide on improving cognitive function in aged mice, 15-17 month old C57BL / 6 mice were treated daily with saline vehicle (one male and two female mice; three mice in total) or 5 nmol of exenatide per kg body weight (four male and three female mice; seven mice in total) for 2-4 months. After treatment, the mice were subjected to the Y maze test. Figure 6 As shown, mice treated with exenatide spent more time in the novel arm, suggesting improved spatial memory.

[0093] Exemplary Embodiments

[0094] Example 1. A method of treating a senescence-related brain dysfunction in a subject, the method comprising administering an effective amount of a GLP-1R agonist to the subject, thereby treating the senescence-related brain dysfunction.

[0095] Embodiment 2. The method according to embodiment 1, wherein the GLP-1R agonist is exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, tasmoglutide, PF-06882961, OWL-833, TTP-273 or any other molecule that activates GLP-1R.

[0096] Example 3. The method according to Example 1, further comprising administering a pharmaceutically acceptable carrier together with the GLP-1R agonist.

[0097] Embodiment 4. The method according to embodiment 1, wherein the subject is a mammal.

[0098] Embodiment 5. The method according to embodiment 4, wherein the mammal is a primate.

[0099] Embodiment 6. The method of embodiment 5, wherein the primate is a human.

[0100] Embodiment 7. The method according to embodiment 1, wherein the subject is 50 years old or older.

[0101] Embodiment 8. The method according to embodiment 1, wherein the aging-related brain dysfunction comprises cognitive impairment.

[0102] Embodiment 9. The method according to embodiment 8, wherein the cognitive impairment is any one of the following: attention and concentration, learning tasks and concepts, memory, information processing, visual spatial function, speech production, language comprehension, verbal fluency, problem solving, decision making and executive function.

[0103] Embodiment 10. The method according to embodiment 1, wherein the aging-related brain dysfunction comprises any one of measurable brain structural changes, functional changes and molecular changes.

[0104] Embodiment 11. The method according to embodiment 10, wherein the aging-related measurable structural changes are any one of the following: hippocampal atrophy, cortical atrophy, subcortical structural atrophy, cerebellar atrophy, whole brain atrophy, gray matter microbleeds, white matter microbleeds, lacunes, infarcts, perivascular spaces, white matter intensity changes, and protein species aggregation.

[0105] Embodiment 12. The method according to embodiment 11, wherein the protein species is any one of the following: beta-amyloid protein, Tau protein, alpha-synuclein, TAR DNA binding protein 43 and prion protein.

[0106] Embodiment 13. The method according to embodiment 10, wherein the aging-related measurable structural changes are measured by imaging methods.

[0107] Embodiment 14. The method according to embodiment 13, wherein the imaging method is magnetic resonance imaging (MRI), computed tomography (CT) and / or ultrasonography (US).

[0108] Embodiment 15. The method according to embodiment 10, wherein the aging-related measurable functional changes are altered brain region activation patterns, neuronal activity, functional connectivity, blood-brain barrier leakage, resting blood flow, glucose consumption, metabolite concentrations, neurovascular coupling, or functional hyperemia.

[0109] Embodiment 16. The method according to embodiment 15, wherein the aging-related measurable functional changes are measured by functional imaging or recording methods.

[0110] Embodiment 17. The method according to embodiment 16, wherein the functional imaging or recording method is functional magnetic resonance imaging (fMRI), magnetic resonance imaging (MRSI), hyperpolarized carbon 13 ( 13C) Magnetic resonance spectroscopic imaging (MRSI), ultrasonography (US), positron emission tomography (PET), single photon emission computed tomography (SPECT), electroencephalography (EEG), magnetoencephalography (MEG), functional near-infrared brain imaging (fNIRS), intracortical electrode recording, or deep brain electrode recording.

[0111] Embodiment 18. The method according to embodiment 10, wherein the measurable molecular changes associated with aging are changes in gene expression; DNA transcription; RNA translation; localization of DNA, RNA or protein in brain cells or tissues; or secretion or release of protein, DNA, RNA, mitochondria, cellular components or mitochondrial components into the blood.

[0112] Embodiment 19. The method of embodiment 10, wherein the aging-associated measurable molecular changes are changes in cerebrospinal fluid (CSF) or blood / plasma components.

[0113] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes are suggested to those skilled in the art accordingly, which are included within the spirit and authority of the present application and the scope of the appended claims. In addition, any element or limitation of any invention or embodiment disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment disclosed herein, and all such combinations are intended to be included within the scope of the present invention but are not limited thereto.

Claims

1. A composition for treating aging-related brain dysfunction in a subject, characterized in that: The composition comprises a GLP-1R agonist and is used for treating the aging-related brain dysfunction.

2. The composition for treating aging-related brain dysfunction in a subject according to claim 1, characterized in that: wherein the GLP-1R agonist is exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, tasmoglutide, PF-06882961, OWL-833 or TTP-273 or any other molecule that activates GLP-1R.

3. The composition according to claim 1, characterized in that The composition also includes a pharmaceutically acceptable carrier.

4. The composition according to claim 1, characterized in that wherein the subject is a mammal.

5. The composition according to claim 4, characterized in that Wherein the mammal is a primate.

6. The composition according to claim 5, characterized in that Wherein the primate is a human.

7. The composition according to claim 1, characterized in that wherein the subject is 50 years of age or older.

8. The composition according to claim 1, characterized in that Wherein the aging-related brain dysfunction includes cognitive impairment.

9. The composition according to claim 8, characterized in that The cognitive impairment is any of the following: attention and concentration, learning tasks and concepts, memory, information processing, visual-spatial function, speech production, language comprehension, verbal fluency, problem solving, decision-making, and executive function.

10. The composition according to claim 1, characterized in that The aging-related brain dysfunction includes any of measurable brain structural changes, functional changes, and molecular changes.

11. The composition according to claim 10, characterized in that The aging-related measurable structural changes are any one of the following: hippocampal atrophy, cortical atrophy, subcortical structural atrophy, cerebellar atrophy, global brain atrophy, gray matter microbleeds, white matter microbleeds, lacunes, infarcts, perivascular spaces, white matter intensity changes, and protein species aggregation.

12. The composition according to claim 11, characterized in that The protein species is any one of the following: amyloid β, Tau protein, α-synuclein, TAR DNA binding protein 43 and prion protein.

13. The composition according to claim 10, characterized in that Wherein said aging-associated measurable structural changes are measured by imaging methods.

14. The composition according to claim 13, characterized in that The imaging method is magnetic resonance imaging (MRI), computed tomography (CT) and / or ultrasonography (US).

15. The composition according to claim 10, characterized in that The aging-related measurable functional changes are altered brain region activation patterns, neuronal activity, functional connectivity, blood-brain barrier leakage, resting blood flow, glucose consumption, metabolite concentrations, neurovascular coupling or functional hyperemia.

16. The composition according to claim 15, characterized in that The aging-related measurable functional changes are measured by functional imaging or recording methods.

17. The composition according to claim 16, characterized in that The functional imaging or recording method is functional magnetic resonance imaging (fMRI), magnetic resonance imaging (MRI), hyperpolarized carbon 13 ( 13 C) Magnetic resonance spectroscopic imaging (MRSI), ultrasonography (US), positron emission tomography (PET), single photon emission computed tomography (SPECT), electroencephalography (EEG), magnetoencephalography (MEG), functional near-infrared brain imaging (fNIRS), intracortical electrode recording, or deep brain electrode recording.

18. The composition according to claim 10, characterized in that Wherein the aging-associated measurable molecular changes are changes in gene expression; DNA transcription; RNA translation; localization of DNA, RNA, or protein in brain cells or tissues; or secretion or release of protein, DNA, RNA, mitochondria, cellular components, or mitochondrial components into the blood.

19. The composition according to claim 10, characterized in that The aging-associated measurable molecular changes are changes in cerebrospinal fluid (CSF) or blood / plasma components.

20. Use of the composition of any one of claims 1 to 19 in the preparation of a medicament for treating aging-related brain dysfunction in a subject, wherein an effective amount of the medicament is administered to the subject, thereby treating the aging-related brain dysfunction.

Citation Information

Cited By

  • Pharmaceutical composition and application thereof in preparation of medicine for treating CSVD

    CN122351487A